Asthma & Allergy Foundation of America ... Allergy-test-based elimination diets for the treatment of eosinophilic esophagitis: A systematic review of their efficacy. J Clin Med.

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

This can lead to inflammation and an increased risk of eosinophilic asthma. If you have severe asthma or your asthma symptoms do not improve with standard treatments, your healthcare provider may ...

which is similar to the inflammatory processes seen in asthma and eosinophilic rhinosinusitis. This has led to a reevaluation of the diagnostic criteria and treatment approaches for EOM ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Previously approved in China for severe eosinophilic asthma in adult and adolescent individuals of ... "China’s NMPA approves GSK’s Nucala for CRSwNP treatment" was originally created and published by ...

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

Mepolizumab is already approved in China as an add-on maintenance treatment for adults and adolescents aged 12 years and older with severe eosinophilic asthma as well as for adults with eosinophilic ...